Genomic signatures in B-cell lymphoma: How can these improve precision in diagnosis and inform prognosis?

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Blood reviews

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.blre.2015.08.002PMID 26432520
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Novel targeted therapies in diffuse large B-cell lymphoma.

  2015cited by this paper
• Global microRNA expression profiling uncovers molecular markers for classification and prognosis in aggressive B-cell lymphoma.

  2015cited by this paper
• Novel biologic agents for non-Hodgkin lymphoma and chronic lymphocytic leukemia-part 2: adoptive cellular immunotherapy, small-molecule inhibitors, and immunomodulation.

  2015cited by this paper
• Genetic lesions in diffuse large B-cell lymphomas.

  2015cited by this paper
• The preclinical discovery of rituximab for the treatment of non-Hodgkin’s lymphoma

  2015cited by this paper
• Activating somatic mutations in diffuse large B-cell lymphomas: lessons from next generation sequencing and key elements in the precision medicine era

  2015cited by this paper
• A phase 2 study of weekly temsirolimus and bortezomib for relapsed or refractory B‐cell non‐Hodgkin lymphoma: A Wisconsin Oncology Network study

  2015cited by this paper
• Ibrutinib: First Global Approval

  2014cited by this paper
• A treatment for activated B-cell-like DLBCL?

  2014cited by this paper
• Next generation sequencing and the management of diffuse large B-cell lymphoma: from whole exome analysis to targeted therapy.

  2014cited by this paper
• Variability in DNA methylation defines novel epigenetic subgroups of DLBCL associated with different clinical outcomes.

  2014cited by this paper
• Genome-wide copy-number analyses reveal genomic abnormalities involved in transformation of follicular lymphoma.

  2014cited by this paper
• Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study.

  2013cited by this paper
• Genome‐wide methylation analyses identify a subset of mantle cell lymphoma with a high number of methylated CpGs and aggressive clinicopathological features

  2013cited by this paper
• Landscape of somatic mutations and clonal evolution in mantle cell lymphoma

  2013cited by this paper
• Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study

  2013cited by this paper
• Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing.

  2013cited by this paper
• Analysis of FOXO1 mutations in diffuse large B-cell lymphoma.

  2013cited by this paper
• Obinutuzumab (GA101) in patients with relapsed/refractory indolent non-Hodgkin lymphoma: results from the phase II GAUGUIN study.

  2013cited by this paper
• Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma

  2013cited by this paper
• MYD88 expression and L265P mutation in diffuse large B-cell lymphoma.

  2013cited by this paper
• CCND2 rearrangements are the most frequent genetic events in cyclin D1(-) mantle cell lymphoma.

  2013cited by this paper
• Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma.

  2012cited by this paper
• Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics

  2012cited by this paper
• Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma.

  2012cited by this paper
• MicroRNA profiling of follicular lymphoma identifies microRNAs related to cell proliferation and tumor response

  2012cited by this paper
• Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing

  2012cited by this paper
• Nodal marginal zone lymphoma: gene expression and miRNA profiling identify diagnostic markers and potential therapeutic targets.

  2012cited by this paper
• Genome-wide miRNA profiling of mantle cell lymphoma reveals a distinct subgroup with poor prognosis.

  2012cited by this paper
• Exome-assistant: a rapid and easy detection of disease-related genes and genetic variations from exome sequencing

  2012cited by this paper
• BCL2 Predicts Survival in Germinal Center B-cell–like Diffuse Large B-cell Lymphoma Treated with CHOP-like Therapy and Rituximab

  2011cited by this paper
• MicroRNA profiles of t(14;18)-negative follicular lymphoma support a late germinal center B-cell phenotype.

  2011cited by this paper
• Genome wide copy number analysis of paediatric Burkitt lymphoma using formalin‐fixed tissues reveals a subset with gain of chromosome 13q and corresponding miRNA over expression

  2011cited by this paper
• Relapsed/refractory diffuse large B-cell lymphoma.

  2011cited by this paper
• Frequent mutation of histone modifying genes in non-Hodgkin lymphoma

  2011cited by this paper
• Improved survival with vemurafenib in melanoma with BRAF V600E mutation.

  2011cited by this paper
• Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia.

  2010cited by this paper
• Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma

  2010cited by this paper
• Detection of genomic aberrations in molecularly defined Burkitt’s lymphoma by array-based, high resolution, single nucleotide polymorphism analysis

  2010cited by this paper
• Role of the microenvironment in mantle cell lymphoma: IL-6 is an important survival factor for the tumor cells.

  2010cited by this paper
• DNA methylation signatures define molecular subtypes of diffuse large B-cell lymphoma.

  2010cited by this paper
• Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma.

  2010cited by this paper
• Mechanisms of chromosomal rearrangement in the human genome

  2010cited by this paper
• High resolution analysis of follicular lymphoma genomes reveals somatic recurrent sites of copy‐neutral loss of heterozygosity and copy number alterations that target single genes

  2010cited by this paper
• Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas

  2010cited by this paper
• Roles for NBS1 in alternative nonhomologous end-joining of V(D)J recombination intermediates.

  2009cited by this paper
• The significance of TP53 in lymphoid malignancies: mutation prevalence, regulation, prognostic impact and potential as a therapeutic target

  2009cited by this paper
• TNFAIP3/A20 functions as a novel tumor suppressor gene in several subtypes of non-Hodgkin lymphomas.

  2009cited by this paper
• Recurrent mutations of the STAT6 DNA binding domain in primary mediastinal B-cell lymphoma.

  2009cited by this paper
• Cancer genome sequencing: a review.

  2009cited by this paper
• Targeted disruption of the S1P2 sphingosine 1-phosphate receptor gene leads to diffuse large B-cell lymphoma formation.

  2009cited by this paper
• Essential role of MALT1 protease activity in activated B cell-like diffuse large B-cell lymphoma

  2009cited by this paper
• A purine scaffold Hsp90 inhibitor destabilizes Bcl6 and has specific anti-tumor activity in Bcl6 dependent B-cell lymphomas

  2009cited by this paper
• Array-based DNA methylation profiling in follicular lymphoma

  2009cited by this paper
• Mutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphoma

  2009cited by this paper
• Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma.

  2009cited by this paper
• Whole genome scanning as a cytogenetic tool in hematologic malignancies.

  2008cited by this paper
• Chromosomal alterations detected by comparative genomic hybridization in subgroups of gene expression-defined Burkitt’s lymphoma

  2008cited by this paper
• Next-generation DNA sequencing

  2008cited by this paper
• The tumor microenvironment and its role in promoting tumor growth

  2008cited by this paper
• Germinal centres: role in B-cell physiology and malignancy

  2008cited by this paper
• Conditional Immortalization of Human B Cells by CD40 Ligation

  2008cited by this paper
• Immunosuppressive mechanisms in human tumors: why we still cannot cure cancer.

  2008cited by this paper
• Prognostic significance of VEGF, VEGF receptors, and microvessel density in diffuse large B cell lymphoma treated with anthracycline-based chemotherapy

  2008cited by this paper
• DNA methylation profiles in diffuse large B-cell lymphoma and their relationship to gene expression status

  2008cited by this paper
• Integrated biochemical and computational approach identifies BCL6 direct target genes controlling multiple pathways in normal germinal center B cells.

  2008cited by this paper
• Stromal gene signatures in large-B-cell lymphomas.

  2008cited by this paper
• G.O.D.’s Holy Grail: Discovery of the RAG Proteins

  2008cited by this paper
• BCL6-mediated Attenuation of DNA Damage Sensing Triggers Growth Arrest and Senescence through a p53-dependent Pathway in a Cell Context-dependent Manner*

  2008cited by this paper
• The biochemistry of somatic hypermutation.

  2008cited by this paper
• Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma.

  2008cited by this paper
• Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways

  2008cited by this paper
• Translocations involving 8q24 in Burkitt lymphoma and other malignant lymphomas: a historical review of cytogenetics in the light of todays knowledge

  2008cited by this paper
• Down-regulation of the TGF-beta target gene, PTPRK, by the Epstein-Barr virus encoded EBNA1 contributes to the growth and survival of Hodgkin lymphoma cells.

  2008cited by this paper
• Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAILreceptor-2, predict for poor survival in diffuse large B-cell lymphoma.

  2007cited by this paper
• Specific secondary genetic alterations in mantle cell lymphoma provide prognostic information independent of the gene expression-based proliferation signature.

  2007cited by this paper
• Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma

  2007cited by this paper
• Comprehensive Analysis of Copy Number and Allele Status Identifies Multiple Chromosome Defects Underlying Follicular Lymphoma Pathogenesis

  2007cited by this paper
• Molecular diagnosis of Burkitt's lymphoma.

  2006cited by this paper
• JAK signaling globally counteracts heterochromatic gene silencing

  2006cited by this paper
• FAS Death Domain Deletions and Cellular FADD-like Interleukin 1β Converting Enzyme Inhibitory Protein (Long) Overexpression: Alternative Mechanisms for Deregulating the Extrinsic Apoptotic Pathway in Diffuse Large B-Cell Lymphoma Subtypes

  2006cited by this paper
• Loss of major histocompatibility class II gene and protein expression in primary mediastinal large B-cell lymphoma is highly coordinated and related to poor patient survival.

  2006cited by this paper
• A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling.

  2006cited by this paper
• Stem cell factor promotes mast cell survival via inactivation of FOXO3a-mediated transcriptional induction and MEK-regulated phosphorylation of the proapoptotic protein Bim.

  2005cited by this paper
• A microRNA polycistron as a potential human oncogene

  2005cited by this paper
• Distinct Subsets of Primary Effusion Lymphoma Can Be Identified Based on Their Cellular Gene Expression Profile and Viral Association

  2005cited by this paper
• The biology of human lymphoid malignancies revealed by gene expression profiling.

  2005cited by this paper
• miR-15 and miR-16 induce apoptosis by targeting BCL2.

  2005cited by this paper
• Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in the MedB-1 mediastinal lymphoma line.

  2005cited by this paper
• Loss of major histocompatibility class II expression in non-immune-privileged site diffuse large B-cell lymphoma is highly coordinated and not due to chromosomal deletions.

  2005cited by this paper
• Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction.

  2005cited by this paper
• Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling.

  2005cited by this paper
• Gene expression profiling in follicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment.

  2005cited by this paper
• Homozygous deletion of SOCS1 in primary mediastinal B-cell lymphoma detected by CGH to BAC microarrays

  2005cited by this paper
• Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response.

  2004cited by this paper
• A tiling resolution DNA microarray with complete coverage of the human genome

  2004cited by this paper
• Small lymphocytic lymphoma, marginal zone B-cell lymphoma, and mantle cell lymphoma exhibit distinct gene-expression profiles allowing molecular diagnosis.

  2004cited by this paper
• Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells.

  2004cited by this paper
• Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma.

  2004cited by this paper
• RAG proteins shepherd double-strand breaks to a specific pathway, suppressing error-prone repair, but RAG nicking initiates homologous recombination.

  2004cited by this paper

• High SRD5A3 expression is correlated with promotion of proliferation and inhibition of apoptosis in B-cell non-Hodgkin lymphoma and suggests a poor prognosis

  2025cites this paper
• High‐grade B‐cell lymphoma not otherwise specified, with diffuse large B‐cell lymphoma gene expression signatures: Genomic analysis and potential therapeutics

  2024cites this paper
• Relationship between BCL2 mutations and follicular lymphoma outcome in the chemoimmunotherapy era

  2023cites this paper
• The kava chalcone flavokawain B exerts inhibitory activity and synergizes with BCL-2 inhibition in malignant B-cell lymphoma.

  2023cites this paper
• Synthetic lethality of drug-induced polyploidy and BCL-2 inhibition in lymphoma

  2023cites this paper
• Application of next-generation sequencing in diffuse large B-cell lymphoma.

  2023cites this paper
• Genomic profiling identifies distinct genetic subtypes in extra-nodal natural killer/T-cell lymphoma

  2022cites this paper
• The Era of Genomic Research for Lymphoma: Looking Back and Forward

  2022cites this paper
• Diffuse large B-cell lymphoma: Time to focus on circulating blood nucleic acids?

  2020cites this paper
• Burkitt Lymphoma and Diffuse Large B-Cell Lymphoma

  2019cites this paper
• L-Type Cav 1.2 Calcium Channel-α-1C Regulates Response to Rituximab in Diffuse Large B-Cell Lymphoma

  2019cites this paper
• Cutaneous lesions of angioimmunoblastic T‐cell lymphoma: Clinical, pathological, and immunophenotypic features

  2019cites this paper
• Oral lesion as the primary diagnosis of non-Hodgkin’s lymphoma: a 20-year experience from an oral pathology service and review of the literature

  2019cites this paper
• Phase I/II study of dasatinib and exploratory genomic analysis in relapsed or refractory non‐Hodgkin lymphoma

  2018cites this paper
• Molecular and Genomic Landscape of Peripheral T-Cell Lymphoma.

  2018cites this paper
• Prognostication of diffuse large B-cell lymphoma in the molecular era: moving beyond the IPI.

  2018cites this paper
• Validation of a Multiplexed Gene Signature Assay for Diagnosis of Canine Cancers from Formalin‐Fixed Paraffin‐Embedded Tissues

  2017cites this paper
• Complex analysis of the TP53 tumor suppressor in mantle cell and diffuse large B-cell lymphomas.

  2017cites this paper
• Oncogenic Signaling Pathways and Pathway-Based Therapeutic Biomarkers in Lymphoid Malignancies.

  2017cites this paper
• Current advances of long non-coding RNA highly upregulated in liver cancer in human tumors

  2017cites this paper
• Role of activation-induced cytidine deaminase (AID) in follicular lymphoma biology

  2017cites this paper
• Clinical approach to diffuse large B cell lymphoma.

  2016cites this paper
• Co-Overexpression Myc and Bcl-2 Predicts Inferior Survival in Mantle Cell Lymphoma

  2016cites this paper
• Complex analysis of the TP 53 tumor suppressor in mantle cell and diffuse large B-cell lymphomas

  year unknowncites this paper